COVID-19 and Tissue Damage in Vital Organs

Summary

The study will be conducted in Dokuz Eylül University Hospital, COVID-19 (Coronavirus Disease 2019) intensive care unit. Three primary conditions will be sought for participants:

1. Cases whose treatment process resulted in death will be included in the study.
2. The cases must be confirmed with the diagnosis of COVID-19 by the RT-PCR (real time polymerase chain reaction) test.
3. The first-degree relatives must consent for the participation of the subjects in the study by their first-degree relatives.

In the study, samples will be taken from the liver, kidney, lung, and heart. The samples will be stored in a protective solution and sent to the pathology unit. The examinations will determine the microscopic damage to these organs caused by COVID-19.

Also, the presence of the SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) will be investigated by RT-PCR in tissues. The presence of ACE-2 (angiotensin converting enzyme 2) receptor and SARS-CoV-2 nucleoprotein antibody will be investigated by histochemical examination in tissues.

Conditions

• Covid19
• Postmortem Changes

Interventions

PROCEDURE

Liver, lung, heart and kidney biopsy

Liver, lung, heart and kidney biopsies will be performed on each case in the COVID-19 group.

Sponsors & Collaborators

• Dokuz Eylul University

  lead OTHER

Principal Investigators

• Ali N Gökmen, MD, PhD · Dokuz Eylul University, Department of Anaesthesiology and Reanimation, Division of Intensive Care

• Mehmet N Yakar, MD, PhD · Dokuz Eylul University, Department of Anaesthesiology and Reanimation, Division of Intensive Care

• Safiye Aktaş, MD, PhD · Dokuz Eylul University, Oncology Institute, Department of Basic Oncology

• Bilgin Cömert, MD, PhD · Dokuz Eylul University, Department of Internal Medicine, Division of Intensive Care

• Begüm Ergan, MD, PhD · Dokuz Eylul University, Department of Chest Disease, Division of Intensive Care

• Bişar Ergün, MD, PhD · Dokuz Eylul University, Department of Internal Medicine, Division of Intensive Care

• Fırat Bayraktar, MD, PhD · Dokuz Eylul University, Department of Internal Medicine, Division of Endocrinology and Metabolism

• Eyüp S Uçan, MD, PhD · Dokuz Eylul University, Department of Chest Disease

• Aylin Erol · Dokuz Eylul University, Oncology Institute

• Özde E Gökbayrak · Dokuz Eylul University, Oncology Institute

Study Design

Allocation

NA

Purpose

DIAGNOSTIC

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-01-01

Primary Completion

2021-06-01

Completion

2022-01-01

Countries

• Turkey (Türkiye)

Study Locations